| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_560f81a97f1a786a5623d3203bfcee18 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2002-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L33-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L33-105
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-752
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-685
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7048 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-685
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A23L33-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A23L33-105
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-752
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 |
| filingDate |
2018-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c7755df889d712570bdf18d1b724ffcf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7818bd884bba8a4e1e648e3d92c9695c |
| publicationDate |
2019-11-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-110494144-A |
| titleOfInvention |
Composition for the treatment and/or prevention of Alzheimer's disease |
| abstract |
The present invention provides compositions for the treatment and/or prevention of Alzheimer's disease, which have improved therapeutic or preventive effects and reduced side effects. The composition for the treatment and/or prevention of Alzheimer's disease of the present invention contains at least one selected from the group consisting of glycerophosphocholine (G) and a pharmacologically acceptable salt thereof as the first active ingredient a compound; and at least one compound selected from the group consisting of hesperidin (H), naringin (N), and pharmacologically acceptable salts thereof as the second active ingredient. The composition promotes remyelination, promotes alpha-secretase activity, and also inhibits beta-secretase expression. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113827605-A |
| priorityDate |
2017-04-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |